Technology Innovation Institute’s Secure Systems Research Centre Partners with Purdue University on Game-Changing UAV Security Project
10.3.2021 13:29:00 EET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Purdue University, a world-renowned US-based public research university. The two entities are collaborating on a three-year sophisticated cybersecurity project to ensure Unmanned Aerial Vehicles (UAVs) can be used safely and efficiently in urban operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005409/en/
Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) - (Photo: AETOSWire)
Secure Systems Research Centre is one of initial seven dedicated research centres at TII. The research collaboration with Purdue University, titled ‘Cybersecurity for UAS Operations in Urban Environment’, includes the study of security and resilience in cyber-physical and autonomous systems. The project examines safety challenges that Unmanned Aerial Systems (UASs) experience in operating environments. These systems and vehicles are vulnerable to sophisticated cyberattacks in terms of communication, navigation, surveillance, and command and control. The outcome of this research will help other research at Secure Systems Research Centre in the future.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is becoming increasingly complex. This is evidenced by the rising number of cyberattacks and surveillance breaches that occur daily. We must regain control over critical digital systems. We are optimistic that the research outcomes at TII’s Secure Systems Research Centre will allow us to gain the upper hand in the fight against these malicious attacks.”
He added: “We are delighted to have the Purdue Team led by Prof. Inseok Hwang of School of Aeronautics and Astronautics partner on making cyber-physical and autonomous systems secure and resilient to malware using their state of the art autonomous drone testing facility. This will enable commercial autonomous drones and robots growth in the UAE and worldwide, opening new opportunities to enterprises and making their use safer for all people.”
A multidisciplinary group of researchers from Purdue University will join forces with TII’s Secure Systems Research Centre team.
The research project comprises four phases of development. First, it will carry out a modelling and analysis of UAS security. Second, it will develop algorithms and methodologies for high-assurance autonomy. Third, it will construct an experimental environment and work to simulate safe and secure urban UAS operations. Finally, it will test and validate mitigation strategies in a scaled, mixed-reality testbed.
This three-year project is led by Prof. Inseok Hwang as the principal investigator. Prof. Hwang is assisted on this project by two co-researchers from Purdue University – Prof. James Goppert, a visiting assistant professor at the School of Aeronautics and Astronautics and managing director of the UAS Research and Test Facility; and Prof. Dongyan Xu, the Samuel D. Conte Professor of Computer Science and Director of CERIAS (Center for Education and Research in Information Assurance and Security), Purdue’s cybersecurity research and education center.
Prof. Hwang will assess potential cyberattacks on the systems, Prof. Xu will conduct resource-efficient encryption, multi-UAS communications, and other research from the cyber perspective while Prof. Goppert will test the drones in a special mixed reality environment he will design and build.
Prof. Hwang said: “This landmark project comes at a time of growing reliance on UASs across various sectors – from security to medicine and logistics, and everything in between. We are confident that our partnership will translate into global wins for the international community and lead to many more research milestones in the years to come.”
For more information, please visit www.tii.ae and https://securesystems.tii.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005409/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
